BridgeBio Pharma, Inc. (BBIO) community

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30

$78.30+0.13 (+0.17%)

Close on Nov 13, 2026Market cap $15.25BP/E –Yield –

Community

Notes and questions about BridgeBio Pharma from other investors

No posts about BBIO yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in BridgeBio Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BBIO.

Compare: BBIO vs KNSA · BBIO vs IONS · BBIO vs INSM · BBIO vs SRPT · BBIO vs PTCT

Revenue growth167.3% · median -0.7%

Gross margin94.3% · median 90.2%

Operating margin-38.5% · median -2.5%

Company	Revenue	Growth
SRPT	$1.96B	-18.9%
INSM	$1.52B	+240.0%
PTCT	$1.16B	-35.1%
IONS	$960.09M	-0.7%
KNSA	$945.96M	+58.2%
BBIO	$945.54M	+167.3%

Company

Next earnings (est.): Feb 23, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 834
Held by institutions: 99.4%
Auditor: Deloitte & Touche LLP
SEC CIK: 1743881

Advertisement
300 × 250

See a number that looks wrong?